Alzeca Biosciences

Alzeca Biosciences is a biotechnology startup based in the United States, founded in 2012. The company's focus is on the early detection of Alzheimer's Disease pathology, a crucial need considering the projected quadrupling of Alzheimer's cases by 2050. With the disease pathology beginning to accumulate years prior to cognitive onset, early detection can pave the way for more effective treatment. Alzeca aims to achieve this through its best-in-class imaging technologies, which have garnered support from private investors and grants from esteemed organizations like the Cure Alzheimer’s Fund, Alzheimer’s Association, NIH, and Alliance for NanoHealth. The team behind Alzeca Biosciences brings together over 25 years of experience in drug development and features renowned Key Opinion Leaders on its Scientific Advisory Board. The company's technologies hold the potential to improve patient selection and monitoring in clinical trials and aid in the differential diagnosis of patients with Mild Cognitive Impairment. Notably, Alzeca Biosciences secured a Series A investment on 31 October 2019, signifying a confidence in its innovative approach to tackling Alzheimer's Disease. With its impactful mission and experienced team, Alzeca Biosciences is poised to make significant strides in the biotechnology and healthcare industries.